PHYHIPL: A Potential Drug Target for Cellular Signaling and Marker

Target Name: PHYHIPL

NCBI ID: G84457

PHYHIPL

Other Name(s): PHIPL_HUMAN | Phytanoyl-CoA 2-hydroxylase interacting protein like, transcript variant 1 | PHYHIPL variant 1 | Phytanoyl-CoA hydroxylase-interacting protein-like | KIAA1796 | phytanoyl-CoA 2-hydroxylase interacting protein like | Phytanoyl-CoA hydroxylase-interacting protein-like (isoform 1) | phytanoyl-CoA hydroxylase-interacting protein-like

PHYHIPL: A Potential Drug Target for Cellular Signaling and Marker

PHYHIPL (PHIPL\\_HUMAN) is a protein that is expressed in a variety of tissues in the human body, including the brain, heart, liver, and muscle. It is a member of the phospholipase C family, which is a group of enzymes that are involved in the breakdown of phospholipids in cell membranes. This protein is of particular interest as a potential drug target or biomarker because of its role in the regulation of cellular signaling pathways.

PHYHIPL has been shown to play a role in a number of important cellular processes in the brain, including the regulation of neurotransmitter release, the formation of neural circuits, and the maintenance of cellular structure. It is also involved in the regulation of inflammation and immune responses.

One of the key functions of PHYHIPL is its role in the regulation of neurotransmitter release. PHYHIPL has been shown to play a role in the breakdown of the phospholipid membrane, which is the outer layer of the cell membrane. This process is important for the release of neurotransmitters, such as dopamine and serotonin, which are involved in a variety of cellular signaling pathways.

PHYHIPL is also involved in the regulation of cellular structure. It is a member of the phospholipase C family, which is a group of enzymes that are involved in the breakdown of phospholipids in cell membranes. This means that PHYHIPL is involved in the regulation of the structure and composition of cell membranes, which is important for the function of many cellular processes.

In addition to its role in the regulation of neurotransmitter release and cellular structure, PHYHIPL is also involved in the regulation of inflammation and immune responses. It has been shown to play a role in the regulation of inflammation by participating in the synthesis and activation of many immune cells, including natural killer cells, T-cells, and inflammation-promoting cells.

PHYHIPL is also involved in the regulation of cell division and the maintenance of cellular immortality. It has been shown to play a role in the regulation of cell division by participating in the association of the cyclin D1 with the protein p21, a negative regulator of cell division.

PHYHIPL is also involved in the regulation of the immune response. It has been shown to play a role in the regulation of immune responses by participating in the regulation of the production and activation of immune cells, including natural killer cells, T-cells, and B-cells.

In conclusion, PHYHIPL is a protein that is expressed in a variety of tissues in the human body and is involved in a number of important cellular processes, including the regulation of neurotransmitter release, cellular structure, inflammation, and immune responses. Its role in these processes makes it an attractive target for the development of new drugs or biomarkers for a variety of diseases.

Protein Name: Phytanoyl-CoA 2-hydroxylase Interacting Protein Like

Functions: May play a role in the development of the central system

The "PHYHIPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHYHIPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets